Carcinoma, Non-Squamous Non-Small Cell LungPhase 3IMpower130NCT02367781
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
A Phase 3 study testing Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin and Nab-Paclitaxel in people with Carcinoma, Non-Squamous Non-Small Cell Lung, run by Hoffmann-La Roche at 132 sites in 8 countries.
Trial summary
This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel compared with treatment with carboplatin+nab-paclitaxel in chemotherapy-naive participants… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Carcinoma, Non-Squamous Non-Small Cell Lung
- What is being tested?
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin and Nab-Paclitaxel
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 723 participants
- Where
- 132 sitesin 8 countries
- Study dates
- 16 Apr 2015to 18 Jan 2021
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Histologically or cytologically confirmed, Stage IV non-squamous NSCLC
- Participants with no prior treatment for Stage IV non-squamous NSCLC
- Previously obtained archival tumor tissue or tissue obtained from fresh biopsy at screening
- Measurable disease, as defined by RECIST v1.1
- Adequate hematologic and end organ function
Who cannot join
- Cancer-Specific Exclusions:
- Active or untreated central nervous system metastases
- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
- General Medical Exclusions:
- Pregnant or lactating women
- History of autoimmune disease
Show all 13Show fewer
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted
- Positive test for human immunodeficiency virus
- Active hepatitis B or hepatitis C
- Severe infection within 4 weeks prior to randomization
- Significant cardiovascular disease
- Illness or condition that interferes with the participant's capacity to understand, follow and/or comply with study procedures
- Prior treatment with cluster of differentiation 137 agonists or immune checkpoint blockade therapies, anti-programmed death-1, and anti-PD-L1 therapeutic antibodies
Trial locations and contacts
132 sites in 8 countries.
132 sites in 8 countries
United States57 sites
University Cancer & Blood Center, LLC; Research
Athens, Georgia, 30607
Walter Reed National Military Medical Center
Bethesda, Maryland, 20814
Center For Cancer and Blood Disorders
Bethesda, Maryland, 20817
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
Carrollton, Georgia, 30117
Presbyterian Hospital
Charlotte, North Carolina, 28204
University Oncology Associates
Chattanooga, Tennessee, 37403
SCRI Tennessee Oncology Chattanooga
Chattanooga, Tennessee, 37404
University of Illinois at Chicago
Chicago, Illinois, 60612
The Christ Hospital
Cincinnati, Ohio, 45219
Mark H. Zangmeister Center
Columbus, Ohio, 43219
University of Miami School of Medicine - Sylvester at Deerfield
Deerfield Beach, Florida, Suite 200
SCRI The Center For Cancer and Blood Disorders
Denton, Texas, 76210
Duke University Medical Center; Department of Medicine
Durham, North Carolina, 27710
Englewood Hospital and Medical Center
Englewood, New Jersey, 07631
Southcoast Health System
Fairhaven, Massachusetts, 02719
SCRI Florida Cancer Specialists South
Fort Myers, Florida, 33916
Fort Wayne Med Oncology & Hematology Inc
Fort Wayne, Indiana, 46845
Banner MD Anderson Cancer Center
Greeley, Colorado, 85234
Greenville Health System; Cancer Center
Greenville, South Carolina, 29605-4292
Oncology Hematology Care, Inc.
Hamilton, Ohio, 45103
Pinnacle Health
Harrisburg, Pennsylvania, 17110
University of Texas M.D. Anderson Cancer Center
Houston, Texas, 77030
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242-1083
Joliet Oncology-Hematology; Associates, Ltd.
Joliet, Illinois, 60435
Lancaster General Hospital
Lancaster, Pennsylvania, 17604
Suburban Hematology / Oncology Associates
Lawrenceville, Georgia, 30046
Lahey Clinic Med Ctr
Lexington, Kentucky, 02421
Southeast Nebraska Cancer Ctr
Lincoln, Nebraska, 68510
Saint Barnabas Medical Center
Livingston, New Jersey, 07039
Cancer Inst. of New Jersey
New Brunswick, New Jersey, 08901
Laura and ISAAC Perlmutter Cancer Center at NYU Langone.
New York, New York, 10016
Southeastern Regional Medical Center, Inc.
Newnan, Georgia, 30265
Eastern Connecticut Hematology and Oncology Associates; (ECHO)
Norwich, Connecticut, 06360
Kaiser Permanente Oakland Medical Center
Oakland, California, 94611
Florida Hospital
Orlando, Florida, 32803
Illinois Cancer Care
Peoria, Illinois, 61615
Rhode Island Hospital
Providence, Rhode Island, 02903
Quincy Medical Group
Quincy, Illinois, 62301
Va Sierra Nevada Health Care System
Reno, Nevada, 89502
Mayo Clinic
Rochester, Minnesota, 55905
Kaiser Permanente Medical Center - Roseville
Roseville, California, 95661
Kaiser Permanente - Sacramento Medical Center and Medical Offices
Sacramento, California, 95825
W.G. Bill Hefner VA Medical Center
Salisbury, North Carolina
Cancer Care Network of South Texas - SAT & BC
San Antonio, Texas, 78217
Kaiser Permanente - San Francisco Medical Center
San Francisco, California, 94118
Kaiser Permanente - San Jose Medical Center
San Jose, California, 95119
Kaiser Permanente - San Leandro Medical Center
San Leandro, California, 94577
Kaiser Permanente - Santa Clara
Santa Clara, California, 95051
Kaiser Permanente - South San Francisco
South San Francisco, California, 94080
Highlands Oncology Group
Springdale, Arkansas, 72762
Southern Illinois University, Simmons Cancer Institute
Springfield, Illinois, 62794
Florida Cancer Specialists (St. Petersburg - St. Anthony's Professional Building)
St. Petersburg, Florida, 33705
Hematology and Oncology Associates at Bridgepoint
Tupelo, Mississippi, 38801
Kaiser Permanente; Oncology Clinical Trials
Vallejo, California, 94589
Kaiser Permanente - Walnut Creek
Walnut Creek, California, 94596
SCRI Florida Cancer Specialists East
West Palm Beach, Florida, 33401
Clinical Research Alliance
Westbury, New York, 11590
Germany25 sites
Charite - Universitätsmedizin Berlin; Klinik fur Infektiologie und Pneumologie
Berlin, 13353
Klinikum Chemnitz gGmbH
Chemnitz, 09116
Bezirksklinikum Obermain
Ebensfeld, 96250
Helios Klinikum Erfurt
Erfurt, 99089
St. Antonius Hospital
Eschweiler, 52249
Klinikum Esslingen GmbH; Frauenklinik
Esslingen am Neckar, 73730
Malteser Krankenhaus St. Franziskus-Hospital
Flensburg, 24939
Krankenhaus Nordwest
Frankfurt am Main, 60488
Asklepios Fachkliniken GmbH
Gauting, 82131
SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie
Gera, 07548
Robert Bosch Krankenhaus; Pneumologie und pneumologische Onkologie
Gerlingen, 70839
Medizinische Hochschule Hannover
Hanover, 30625
Thoraxklinik Heidelberg gGmbH
Heidelberg, 69126
Fachklinik für Lungenerkrankungen
Immenhausen, 34376
St. Vincentius Kliniken Karlsruhe
Karlsruhe, 76137
Klinikum Kassel; Hautklinik
Kassel, 34125
Katholisches Klinikum Marienhof
Koblenz Am Rhein, 56073
Universitatsklinikum Schleswig-Holstein; Klinik fuer Innere Medizin I
Lübeck, 23538
Klinikum Mannheim GmbH Universitätsklinikum
Mannheim, 68167
Johannes Wesling Klinikum Minden
Minden, 32429
LMU Klinikum der Universitat Munchen
München, 80337
Universitätsklinikum Tübingen
Tübingen, 72076
Praxis fur Haematologie und Internistische Onkologie
Velbert, 42551
Schwarzwald-Baar Klinikum/VS GmbH; Onkologie/Hämatologie/Infektologie
Villingen-Schwenningen, 78052
Helios Klinik Wuppertal
Wuppertal, 42283
Spain13 sites
Complejo Hospitalario Universitario A Coruña
A Coruña, LA Coruña, 15006
Hospital Santa Creu i Sant Pau
Barcelona, 08041
Hospital de San Pedro de Alcantara
Cáceres, 10003
Consorcio Hospitalario Provincial de Castellon
Castellon de LA Plana/castello de LA Plana, Castellon, 12002
Hospital Universitario Virgen de Las Nieves
Granada, 18012
Hospital General Universitario de Guadalajara
Guadalajara, 19002
Complejo Hospitalario de Jaen
Jaén, 23007
Hospital Son Llatzer
Palma de Mallorca, Balearic Islands, 07198
Hospital Universitario de Canarias
S. Cristobal de La Laguna, Tenerife, 38320
Hospital Universitario de Torrejon
Torrejón de Ardoz, Madrid, 28850
Hospital General Universitario de Valencia
Valencia, 46014
Hospital NisA 9 de Octubre
Valencia, 46015
Hospital Universitario Miguel Servet; Servicio Oncologia
Zaragoza, 50009
France12 sites
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, 33300
Institut Hospitalier Franco-Britannique; Cancerologie
Levallois-Perret, 92300
Fondation Hopital Saint Joseph;Cardiologie Clinique
Marseille, 13285
Clinique Clementville; Hopital De Jour
Montpellier, 34070
Centre D'oncologie de Gentilly; Service Oncologie Medicale
Nancy, 54100
Clinique Catherine de Sienne
Nantes, 44202
Hopital American de Paris (American Hospital of Paris)
Neuilly-sur-Seine, 92200
HOPITAL DE LA SOURCE; Service de Cardiologie, Point Jaune
Orléans, 45100
Hopital Pontchaillou
Rennes, 35033
Hopital d'Instruction des Armees de Begin
Saint-Mandé, 94160
Centre Hospitalier Regional Sud Reunion; Service de Pneumologie
Saint-Pierre, 97448
CHRU Nancy; Pneumologie
Vandœuvre-lès-Nancy, 54511
Israel10 sites
Assaf Harofeh Medical Center
Beer Yaakov, 70300
Soroka University Medical Centre
Beersheba, 8410101
Hadassah Ein Karem Hospital; Oncology Dept
Jerusalem, 9112000
Meir Medical Center; Oncology
Kfar Saba, 4428164
Galilee Medical Center
Nahariya, 22100
Rabin Medical Center
Petach Tiqwa, 49100
Chaim Sheba Medical Center
Ramat Gan, 5265601
Rambam Health Corporation; Oncology Institute
Rambam, 3525408
Kaplan Medical Center
Rehovot, 7610001
Tel Aviv Sourasky Medical Ctr; Oncology
Tel Aviv, 6423906
Italy6 sites
Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati
Avellino, Campania, 83100
Ospedale Clinicizzato SS Annunziata
Chieti, Abruzzo, 66100
Azienda Osp Uni Seconda Università Degli Studi Di Napoli; Unità Operativa Oncologia Medica
Naples, Campania, 80131
Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale
Naples, Campania, 80131
Ospedale Santa Maria Della; Misericordia Di Perugia; Farmacia Ospedaliera
Perugia, Umbria, 06129
Ospedale Di Macerata; Oncologia
Province of Macerata, The Marches, 62100
Canada5 sites
Royal Victoria Regional Health Centre
Barrie, Ontario, L4M 6M2
William Osler Health Centre
Etobicoke, Ontario, M9V 1R8
Cite de La Sante de Laval; Hemato-Oncologie
Laval, Quebec, H7M 3L9
Hôpital Maisonneuve - Rosemont
Montreal, Quebec, H1T 2M4
BC Cancer - Surrey
Surrey, British Columbia, V3V 1Z2
Belgium4 sites
Cliniques Universitaires St-Luc
Brussels, 1200
CHU Ambroise Paré
Mons, 7000
Werken Glorieux VZW
Ronse, 9600
GasthuisZusters Antwerpen
Wilrijk, 2610
About this study
Official title: A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel compared with treatment with carboplatin+nab-paclitaxel in chemotherapy-naive participants with Stage IV non-squamous NSCLC. Participants were randomized in a 2:1 ratio to Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) or Arm B (Nab-Paclitaxel+Carboplatin).
- Being tested
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin, Nab-Paclitaxel, Pemetrexed
- Medical subject headings
- Carcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibodyDrug
Also called MPDL3280A, RO5541267, Tecentriq
Atezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to "Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin)" and to participants in "Arm B (Nab-Paclitaxel + Carboplatin)" who cross over at progression.
CarboplatinDrug
Carboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
Nab-PaclitaxelDrug
Nab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m^2) on Days 1, 8, and 15 of each 21-day cycle.
PemetrexedDrug
Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.
| Study group | Role | What they receive |
|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Experimental | Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurred first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit. Receives: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Drug: Carboplatin; Drug: Nab-Paclitaxel |
| Arm B (Nab-Paclitaxel+Carboplatin) | Active comparator | Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurred first during induction treatment phase. Participants received best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed was also permitted. Participants who were consented prior to approval of protocol Version 5 were given the option to cross over to receive atezolizumab as monotherapy until disease progression. Receives: Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Drug: Carboplatin; Drug: Nab-Paclitaxel; Drug: Pemetrexed |
What is being measured
The primary outcome is the main question the study is designed to answer.
Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population
PFS is defined as the time between the date of randomization and the date of first documented disease progression as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first in the ITT-WT population.
Measured: Up to approximately 35 months after first patient enrolled
Overall Survival (OS) in the ITT-WT Population
OS is defined as the time between the date of randomization and date of death from any cause in the ITT-WT population.
Measured: Up to approximately 35 months after first patient enrolled
Secondary outcomes (16)
PFS as Determined by the Investigator Using Recist v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population
PFS is defined as the time between the date of randomization and the date of first documented disease progression as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first. The ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation.
Measured: Up to approximately 35 months after first subject enrolled
OS as Determined by the Investigator Using Recist v1.1 in the ITT Population
OS is defined as the time between the date of randomization and date of death from any cause in the ITT population.
Measured: Up to approximately 41 months after first subject enrolled
OS as Determined by the Investigator Using RECIST v1.1 in the PD-L1 Expression Population and PD-L1 Expression WT Population
OS is defined as the time between the date of randomization and date of death from any cause in the PD-L1 Expression Population and PD-L1 Expression WT Population. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation.
Measured: Up to approximately 35 months after first patient enrolled
Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT-WT Population
ORR (confirmation not required) is defined as the proportion of participants with an objective response, either CR or PR, with the use of RECIST v1.1, as determined by the investigator in the ITT-WT population.
Measured: Up to approximately 41 months after first subject enrolled
Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population
ORR (confirmation not required) is defined as proportion of participants with an objective response, either CR or PR, with the use of RECIST v1.1, as determined by investigator in ITT population, PD-L1 Expression population, and PD-L1 Expression WT population. ITT population was defined as all randomized participants, regardless of receipt of the assigned treatment. PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. PD-L1 expression WT population is defined as PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation.
Measured: Up to approximately 35 months after first subject enrolled
Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population
DOR,defined for participants with objective response (OR) as time from 1st documented OR to documented disease progression as determined by investigator using RECIST v1.1,or death from any cause,whichever occurs 1st.ITT defined as all randomized participants,regardless of receipt of assigned treatment.ITT-WT defined as ITT population excluding participants with activating EGFR mutation or ALK translocation.PD-L1 expression population is defined as one of following:PD-L1 IHC TC1/2/3 or IC1/2/3 population,defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue;PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue;PD-L1 IHC TC3 or IC3 population,defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue.PD-L1 expression WT is defined as PD-L1 expression population excluding participants with activating EGFR mutation or ALK translocation.
Measured: Up to approximately 35 months after first subject enrolled
Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population
The OS rate at the 1- and 2-year landmark time points after randomization.
Measured: Up to 41 months after first patient enrolled, years 1 and 2 reported
Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population
The OS rate at the 1- and 2-year landmark time points after randomization in the PD-L1 Expression Population and PD-L1 Expression WT Population. The PD-L1 expression population is defined as one of the following: PD-L1 IHC TC1/2/3 or IC1/2/3 population, defined as ITT participants with PD-L1 IHC TC1/2/3 or IC1/2/3 expression in baseline tumor tissue; PD-L1 IHC TC2/3 or IC2/3 population, defined as ITT participants with PD-L1 IHC TC2/3 or IC2/3 expression in baseline tumor tissue; PD-L1 IHC TC3 or IC3 population, defined as ITT participants with PD-L1 IHC TC3 or IC3 expression in baseline tumor tissue. The PD-L1 expression WT population is defined as the PD-L1 expression population excluding participants with an activating EGFR mutation or ALK translocation.
Measured: Up to 35 months after first patient enrolled, years 1 and 2 reported
Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms in the ITT-WT Population
Defined as time from randomization to confirmed deterioration (10-point change) on the combined European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core (EORTC QLQ-C30) and supplemental lung cancer module (EORTC QLQ-LC13) symptom subscales.
Measured: Up to approximately 35 months after first subject enrolled
Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale
Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms \& are scored at individual symptom level, thus have a dyspnea score, chest pain score, \& cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 \& maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 \& 2, 'Cough' score is mean of question 3 \& 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥0.3 points for dyspnea \& cough symptom scores is considered to be clinically significant; whereas a score change of≥0.5 points for chest pain score is considered to be clinically significant.
Measured: Up to approximately 35 months after first subject enrolled
Percentage of Participants With Adverse Events
Percentage of participants with at least one adverse event. Adverse event onset date before cross over.
Measured: Up to approximately 69 months after first patient enrolled
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
Baseline prevalence and post-baseline incidence of anti-drug antibodies (ADA) to Atezolizumab in the Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed) and Arm B Carboplatin+nab-paclitaxel Crossover Participants
Measured: Up to approximately 35 months after first subject enrolled
Maximum Observed Serum Concentration (Cmax) of Atezolizumab for Patients in Atezolizumab+Carboplatin+Nab-Paclitaxel Arm
Predose samples will be collected on the same day of treatment administration. The infusion duration of atezolizumab will be of 30-60 minutes.
Measured: Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length = 21 days)
Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Atezolizumab+Carboplain+Nab-Paclitaxel
Predose samples will be collected on the same day of treatment administration.
Measured: Cycle 1 Day 21, Cycle 2 Day 21, Cycle 3 Day 21, and Cycle 7 Day 21 (Cycle length = 21 days)
Plasma Concentrations of Carboplatin
Measured: Predose (same day of treatment administration), 5-10 minutes before end of carboplatin infusion, 1 hour after carboplatin infusion (infusion duration=15 to 30 minutes) on Day 1 of Cycle 1 and 3 (1 Cycle=21 days) (up to approximately 35 months)
Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel
Measured: Predose (same day of treatment administration), 5-10 minutes before end of nab-paclitaxel infusion, 1 hour after nab-paclitaxel infusion (infusion duration=30 minutes) on Day 1 of Cycle 1 and 3 (1 Cycle=21 days) (up to approximately 35 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2015 (estimated)
- Study start16 Apr 2015
- Primary completion15 Mar 2018
- Study completion18 Jan 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Carcinoma, Non-Squamous Non-Small Cell LungStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 723 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02367781
- Sponsor's protocol ID
- GO29537
- Other IDs
- 2014-003206-32, 2014
- Acronym
- IMpower130
- Status last verified
- Jul 2021
- First submitted
- 13 Feb 2015
- Last updated
- 9 Aug 2021
- Results posted
- Yes, on ClinicalTrials.gov
Publications
Socinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok TSK, Reck M, Finley GG, Kaul MD, Yu W, Paranthaman N, Bara I, West HJ. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials. JAMA Oncol. 2023 Apr 1;9(4):527-535. doi: 10.1001/jamaoncol.2022.7711.
PubMed 36795388Ton TGN, Pal N, Trinh H, Mahrus S, Bretscher MT, Machado RJM, Sadetsky N, Chaudhary N, Lu MW, Riely GJ. Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data. Clin Cancer Res. 2022 Jul 1;28(13):2844-2853. doi: 10.1158/1078-0432.CCR-22-0471.
PubMed 35511917West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
PubMed 31122901
Study at a glance
From the registry record, last updated by the sponsor on 9 Aug 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
- ClinicalTrials.gov ID
- NCT02367781
- Acronym / sponsor ID
- IMpower130 / GO29537
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 723 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Study start
- 16 Apr 2015 (actual)
- Primary completion
- 15 Mar 2018 (actual)
- Study completion
- 18 Jan 2021 (actual)
- First posted
- 20 Feb 2015 (estimated)
- Results
- Posted 3 Apr 2019
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) in combination with carboplatin+nab-paclitaxel compared with treatment with carboplatin+nab-paclitaxel in chemotherapy-naive participants with Stage IV non-squamous NSCLC. Participants were randomized in a 2:1 ratio to Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) or Arm B (Nab-Paclitaxel+Carboplatin).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin) | Experimental | Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Drug: Carboplatin, Drug: Nab-PaclitaxelParticipants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurred first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit. |
| Arm B (Nab-Paclitaxel+Carboplatin) | Active comparator | Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Drug: Carboplatin, Drug: Nab-Paclitaxel, Drug: PemetrexedParticipants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurred first during induction treatment phase. Participants received best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed was also permitted. Participants who were consented prior to approval of protocol Version 5 were given the option to cross over to receive atezolizumab as monotherapy until disease progression. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Eastern Cooperative Oncology Group performance status of 0 or 1
- Histologically or cytologically confirmed, Stage IV non-squamous NSCLC
- Participants with no prior treatment for Stage IV non-squamous NSCLC
- Previously obtained archival tumor tissue or tissue obtained from fresh biopsy at screening
- Measurable disease, as defined by RECIST v1.1
Key exclusion criteria (13 listed)
- Active or untreated central nervous system metastases
- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
- Pregnant or lactating women
- History of autoimmune disease
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibodyAlso: MPDL3280A, RO5541267, TecentriqAtezolizumab was administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab was administered to participants who were randomized to "Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin)" and to participants in "Arm B (Nab-Paclitaxel + Carboplatin)" who cross over at progression. | Drug | Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin) |
| CarboplatinCarboplatin was administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle. | Drug | Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin) |
| Nab-PaclitaxelNab-paclitaxel was administered as IV infusion at a dose of 100 milligrams per square meter (mg/m^2) on Days 1, 8, and 15 of each 21-day cycle. | Drug | Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin), Arm B (Nab-Paclitaxel+Carboplatin) |
| PemetrexedSwitch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle. | Drug | Arm B (Nab-Paclitaxel+Carboplatin) |
Primary outcome
Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population
Time frame: Up to approximately 35 months after first patient enrolled
PFS is defined as the time between the date of randomization and the date of first documented disease progression as determined by the investigator according to RECIST v1.1 or death from any cause, whichever occurs first in the ITT-WT population.
Overall Survival (OS) in the ITT-WT Population
Time frame: Up to approximately 35 months after first patient enrolled
OS is defined as the time between the date of randomization and date of death from any cause in the ITT-WT population.
16 secondary outcomes
PFS as Determined by the Investigator Using Recist v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population
Time frame: Up to approximately 35 months after first subject enrolled
OS as Determined by the Investigator Using Recist v1.1 in the ITT Population
Time frame: Up to approximately 41 months after first subject enrolled
OS as Determined by the Investigator Using RECIST v1.1 in the PD-L1 Expression Population and PD-L1 Expression WT Population
Time frame: Up to approximately 35 months after first patient enrolled
Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT-WT Population
Time frame: Up to approximately 41 months after first subject enrolled
Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population
Time frame: Up to approximately 35 months after first subject enrolled
Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population
Time frame: Up to approximately 35 months after first subject enrolled
Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population
Time frame: Up to 41 months after first patient enrolled, years 1 and 2 reported
Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population
Time frame: Up to 35 months after first patient enrolled, years 1 and 2 reported
Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms in the ITT-WT Population
Time frame: Up to approximately 35 months after first subject enrolled
Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale
Time frame: Up to approximately 35 months after first subject enrolled
Percentage of Participants With Adverse Events
Time frame: Up to approximately 69 months after first patient enrolled
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
Time frame: Up to approximately 35 months after first subject enrolled
Maximum Observed Serum Concentration (Cmax) of Atezolizumab for Patients in Atezolizumab+Carboplatin+Nab-Paclitaxel Arm
Time frame: Cycle 1 Day 1 and Cycle 3 Day 1 (Cycle length = 21 days)
Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Atezolizumab+Carboplain+Nab-Paclitaxel
Time frame: Cycle 1 Day 21, Cycle 2 Day 21, Cycle 3 Day 21, and Cycle 7 Day 21 (Cycle length = 21 days)
Plasma Concentrations of Carboplatin
Time frame: Predose (same day of treatment administration), 5-10 minutes before end of carboplatin infusion, 1 hour after carboplatin infusion (infusion duration=15 to 30 minutes) on Day 1 of Cycle 1 and 3 (1 Cycle=21 days) (up to approximately 35 months)
Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel
Time frame: Predose (same day of treatment administration), 5-10 minutes before end of nab-paclitaxel infusion, 1 hour after nab-paclitaxel infusion (infusion duration=30 minutes) on Day 1 of Cycle 1 and 3 (1 Cycle=21 days) (up to approximately 35 months)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Aug 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 36795388Socinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok TSK, Reck M, Finley GG, Kaul MD, Yu W, Paranthaman N, Bara I, West HJ. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials. JAMA Oncol. 2023 Apr 1;9(4):527-535. doi: 10.1001/jamaoncol.2022.7711.
- Derived from this study: PubMed 35511917Ton TGN, Pal N, Trinh H, Mahrus S, Bretscher MT, Machado RJM, Sadetsky N, Chaudhary N, Lu MW, Riely GJ. Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data. Clin Cancer Res. 2022 Jul 1;28(13):2844-2853. doi: 10.1158/1078-0432.CCR-22-0471.
- Derived from this study: PubMed 31122901West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
Related trials for Carcinoma, Non-Squamous Non-Small Cell Lung
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruitingPhase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Non-small Cell Lung Cancer
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
Active, not recruitingPhase 1
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
Breast Cancer, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
132 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Carboplatin and Nab-Paclitaxel in people with Carcinoma, Non-Squamous Non-Small Cell Lung, run by Hoffmann-La Roche at 132 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Aug 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 132 sites in United States, Germany, Spain, France, Israel and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 3 Apr 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population (time frame: Up to approximately 35 months after first patient enrolled). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02367781, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Aug 2021.